Epicutaneous allergen application preferentially boosts specific T cell responses in sensitized patients

Scientific Reports

Volumn 7, Issue 1, 2017, Pages

  Campana, Raffaela ^a   Moritz, Katharina ^b   Neubauer, Angela ^c   Huber, Hans ^c   Henning, Rainer ^c   Brodie, Tess M ^d   Kaider, Alexandra ^e   Sallusto, Federica ^d,f   Wöhrl, Stefan ^b   Valenta, Rudolf ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b Universitatsklinik fur Dermatologie   (Austria)

^c BIOMAY AG   (Austria)

^d INSTITUTE FOR RESEARCH IN BIOMEDICINE   (Switzerland)

^e MEDICAL UNIVERSITY OF VIENNA   (Austria)

^f ETH ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ALLERGEN; CYTOKINE; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G;

CELLULAR IMMUNITY; CUTANEOUS DRUG ADMINISTRATION; DESENSITIZATION; HUMAN; HYPERSENSITIVITY; IMMUNIZATION; IMMUNOLOGY; METABOLISM; MONONUCLEAR CELL; SECONDARY IMMUNIZATION; T LYMPHOCYTE;

ADMINISTRATION, CUTANEOUS; ALLERGENS; CYTOKINES; DESENSITIZATION, IMMUNOLOGIC; HUMANS; HYPERSENSITIVITY; IMMUNITY, CELLULAR; IMMUNIZATION; IMMUNIZATION, SECONDARY; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G; LEUKOCYTES, MONONUCLEAR; T-LYMPHOCYTES;

EID: 85029524598     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/s41598-017-10278-1     Document Type: Article

References (30)

1. Turjanmaa, K., et al. EAACI/GA2LEN position paper: Present status of the atopy patch test. Allergy 61, 1377-84 (2006).
2. Focke, M., Swoboda, I., Marth, K., Valenta, R. Developments in allergen-specific immunotherapy: From allergen extracts to allergy vaccines bypassing allergen-specific immunoglobulin E and T cell reactivity. Clin Exp Allergy 40, 385-97 (2010).
3. Haselden, B. M., Kay, A. B., Larché, M. Immunoglobulin E-independent major histocompatibility complex-restricted T cell peptide epitope-induced late asthmatic reactions. J Exp Med 189, 1885-94 (1999).
4. Purohit, A., et al. Clinical effects of immunotherapy with genetically modified recombinant birch pollen Bet v 1 derivatives. Clin Exp Allergy 38, 1514-25 (2008).
5. Campana, R., et al. Non-IgE-mediated chronic allergic skin inflammation revealed with rBet v 1 fragments. J Allergy Clin Immunol 121, 528-30 (2008).
6. Campana, R., et al. Frequent occurrence of T cell-mediated late reactions revealed by atopy patch testing with hypoallergenic rBet v 1 fragments. J Allergy Clin Immunol 137, 601-09 (2016).
7. Niederberger, V., et al. Antigens drive memory IgE responses in human allergy via the nasal mucosa. Int Arch Allergy Immunol 142, 133-44 (2007).
8. Egger, C., Horak, F., Vrtala, S., Valenta, R., Niederberger, V. Nasal application of rBet v 1 or non-IgE-reactive T-cell epitope-containing rBet v 1 fragments has different effects on systemic allergen-specific antibody responses. J Allergy Clin Immunol 126, 1312-15 (2010).
9. Vrtala, S., et al. Conversion of the major birch pollen allergen, Bet v 1, into two nonanaphylactic T cell epitope-containing fragments: Candidates for a novel form of specific immunotherapy. J Clin Invest 99, 1673-81 (1997).
10. Wierenga, E. A., Snoek, M., Bos, J. D., Jansen, H. M., Kapsenberg, M. L. Comparion of diversity and function of house dust mite-specific T lymphocyte clones from atopic and non-atopic donors. Eur J Immunol 20, 1519-26 (1990).
11. Carballido, J. M., et al. T cell epitope specificity in human allergic and nonallergic subjects to bee venom phospholipase A2. J Immunol 150, 3582-91 (1993).
12. Ebner, C., et al. Nonallergic individuals recognize the same T cell epitopes of Bet v 1, the major birch pollen allergen, as atopic patients. J Immunol 154, 1932-40 (1995).
13. Van Overtvelt, L., et al. Assessment of Bet v 1-specific CD4+T cell responses in allergic and nonallergic individuals using MHC class II peptides tetramers. J Immunol 180, 4514-22 (2008).
14. Siroux, V., et al. Specific IgE and IgG measured by MeDALL allergen-chip depend on allergen and route of exposure: The EGEA study. J Allergy Clin Immunol 139, 643-54 (2017).
15. Cabauatan, C. R., et al. Heat-labile Escherichia coli toxin enhances the induction of allergen-specific IgG antibodies in epicutaneous patch vaccination. Allergy 72, 164-68 (2017).
16. Lambrecht, B. N., Peleman, R. A., Bullock, G. R., Pauwels, R. A. Sensitization to inhaled antigen by intratracheal instillation of dendritic cells. Clin Exp Allergy 30, 214-24 (2000).
17. Allam, J. P., et al. Characterization of dendritic cells from human oral mucosa: A new Langerhans' cell type with high constitutive FcepsilonRI expression. J Allergy Clin Immunol 112, 141-48 (2003).
18. Allam, J. P., et al. Phl p 5 resorption in human oral mucosa leads to dose-dependent and time-dependent allergen binding by oral mucosal Langerhans cells, attenuates their maturation, and enhances their migratory and TGF-beta1 and IL-10-producing properties. J Allergy Clin Immunol 126, 638-45 (2010).
19. Allam, J. P., et al. Immunologic response and safety in birch pollen sublingual versus oral vestibule immunotherapy: A pilot study. J Allergy Clin Immunol 133, 1757-59 (2014).
20. Egger, C., et al. Effects of nasal corticosteroids on boosts of systemic allergen-specific IgE production induced by nasal allergen exposure. PLoS One 10, e0114991 (2015).
21. Herrick, C. A., MacLeod, H., Glusac, E., Tigelaar, R. E., Bottomly, K. Th2 responses induced by epicutaneous or inhalational protein exposure are differentially dependent on IL-4. J Clin Invest 105, 765-75 (2000).
22. Tordesillas, L., et al. Skin exposure promotes a Th2-dependent sensitization to peanut allergens. J Clin Invest 124, 4965-75 (2014).
23. Spergel, J. M., et al. Epicutaneous sensitization with protein antigen induces localized allergic dermatitis and hyperresponsiveness to methacholine after single exposure to aerosolized antigen in mice. J Clin Invest 101, 1614-22 (1998).
24. Akei, H. S., Mishra, A., Blanchard, C., Rothenberg, M. E. Epicutaneous antigen exposure primes for experimental eosinophilic esophagitis in mice. Gastroenterology 129, 985-94 (2005).
25. Dioszeghy, V., et al. Epicutaneous immunotherapy results in rapid allergen uptake by dendritic cells through intact skin and downregulates the allergen-specific response in sensitized mice. J Immunol. 186, 5629-37 (2011).
26. Mondoulet, L., et al. Epicutaneous immunotherapy using a new epicutaneous delivery system in mice sensitized to peanuts. Int Arch Allergy Immunol 154, 299-309 (2011).
27. Dioszeghy, V., et al. The regulatory T cells induction by epicutaneous immunotherapy is sustained and mediates long-term protection from eosinophilic disorders in peanut-sensitized mice. Clin Exp Allergy 44, 867-81 (2014).
28. Siebeneicher, S., et al. Epicutaneous immune modulation with Bet v 1 plus R848 suppresses allergic asthma in a murine model. Allergy 69, 328-37 (2014).
29. Campana, R., et al. Altered IgE epitope presentation: A model for hypoallergenic activity revealed for Bet v 1 trimer. Mol Immunol 48, 431-41 (2011).
30. Vrtala, S., et al. Genetic engineering of trimers of hypoallergenic fragments of the major birch pollen allergen, Bet v 1, for allergy vaccination. Vaccine 29, 2140-48 (2011).